Evolving Pathology of Anaplastic Thyroid Carcinoma: Integrating Morphology, Immunohistochemistry, and Molecular Insights Authors: Toru Odate, Tetsuo Kondo Published: 2026 ABSTRACT ABSTRACTAnaplastic thyroid carcinoma (ATC) is a rare malignancy characterized by an extremely aggressive clinical course, in contrast to the typically indolent behavior of most thyroid carcinomas. Recent advances in high‐throughput sequencing technologies have markedly enhanced our understanding of the genetic alterations underlying ATC. These molecular insights have also influenced current clinical management and pathologic classification. In diagnostic pathology, squamous cell carcinoma arising in the thyroid is now recognized as a histologic variant of ATC. The BRAF p.V600E mutation, detected in approximately half of ATCs, represents a clinically significant genetic alteration, as targeted therapies directed against this mutation have been associated with improved clinical outcomes. In addition to advances in molecular pathology, progress has also been made in diagnostic pathology, including expanded recognition of the histologic spectrum of ATC and the development of novel immunohistochemical markers. In this review, we summarize recent advances in the diagnostic and molecular pathology of ATC, aiming to provide both fundamental and practical insights for clinical practice. In diagnostic pathology, ATC often presents significant challenges because of its marked histologic heterogeneity and a broad differential diagnosis. Accordingly, this review provides an overview of both classical knowledge and recent molecular findings related to ATC and integrates these insights to present an updated framework for differential diagnosis and diagnostic approach. In addition, we discuss recent advances in immunohistochemistry, including mutation‐specific antibodies and novel diagnostic markers, and highlight their relevance in the context of contemporary diagnostic pathology and evolving therapeutic strategies.Keywords: anaplastic thyroid carcinoma, BRAF, histology, immunohistochemistry, pathology Abbreviations anaplastic thyroid carcinoma differentiated thyroid carcinoma follicular thyroid carcinoma papillary thyroid carcinoma squamous cell carcinoma Introduction Anaplastic thyroid carcinoma (ATC) is a highly aggressive malignancy composed of undifferentiated tumor cells. These cells show follicular epithelial differentiation and/or are associated with an identifiable differentiated thyroid carcinoma (DTC) precursor lesion [1]. The term undifferentiated thyroid carcinoma is used synonymously. Although ATC accounts for only approximately 1% of all thyroid carcinomas, it is responsible for about 30%–40% of thyroid carcinoma–related deaths. It is therefore associated with an extremely poor prognosis. Historically, the median survival has been reported to be 3–6 months [2]; however, the recent introduction of molecularly targeted therapies has led to measurable improvements in survival outcomes compared with earlier eras [3]. ATC most commonly presents in elderly patients as a rapidly enlarging neck mass [4, 5]. Microscopically, it is characterized by remarkable morphologic heterogeneity [5, 6]. In addition to well‐recognized histologic patterns, several rare and recently described variants have been reported [7, 8, 9]. This marked diversity gives rise to a broad differential diagnosis in surgical pathology practice. Over the past decade, molecular profiling of thyroid tumors has advanced substantially [10, 11]. In ATC, large‐scale genomic studies have delineated the overall landscape of genetic alterations [5, 12, 13, 14, 15]. Comparative analyses with paired differentiated precursor lesions have further clarified the molecular mechanisms underlying progression from DTC to ATC [14, 16, 17, 18, 19, 20, 21]. The most frequent genetic alteration in ATC is a mutation in the TERT (telomerase reverse transcriptase) promoter, detected in approximately 70% of cases. Mutations in TP53, BRAF, and RAS are also commonly observed in ATC. The identification of the BRAF p.V600E mutation in ATC has major therapeutic implications in current clinical practice [22]. ATC also exhibits a broad spectrum of additional genetic alterations, including CDKN2A/2B deletions, alterations in the PI3K/AKT/mTOR pathway, mutations affecting genes involved in the SWI/SNF chromatin remodeling complex, mismatch repair pathway defects, and abnormalities in histone methyltransferase–related genes. In this review, we discuss key issues in the diagnostic and molecular pathology of ATC. We place particular emphasis on recent advances in histopathologic, genomic, and immunohistochemical features, including mutation‐specific antibodies and novel diagnostic markers. We also highlight how these findings can be applied in surgical pathology practice and the clinical management of ATC. Advances in Diagnostic Pathology of ATC Microscopic Features and Their Clinical Relevance in ATC In general, ATC replaces the pre‐existing thyroid parenchyma and infiltrates the surrounding soft tissues and skeletal muscle. Common microscopic features include extensive necrosis, numerous mitotic figures, atypical mitoses, marked nuclear pleomorphism and/or severe cytologic atypia, and prominent vascular invasion. A dense neutrophilic infiltrate is also frequently observed [23, 24]. Although the microscopic appearance of ATC is highly heterogeneous, several representative patterns have been described, including epithelioid, spindle cell, pleomorphic giant cell, osteoclast‐like giant cell, squamous cell, paucicellular, clear cell, rhabdoid cell, and angiomatoid types [5, 25, 26] (Figure 1). The prognostic significance of these histologic subtypes remains uncertain. Some studies have reported that these subtypes are not associated with distinct prognostic differences [5], whereas others suggest that ATCs exhibiting epithelial growth patterns may be associated with a more favorable prognosis [27]. Emerging evidence also indicates that certain histologic patterns tend to correlate with specific genetic alterations. In particular, the spindle cell type is more commonly associated with RAS‐mutated ATCs, while the epithelioid and squamous cell types tend to harbor BRAF mutations [5, 17, 28]. Rare histologic variants have also been reported, including glomangiosarcoma‐like [8] and plasmacytoma‐like [9] patterns. ATC may additionally exhibit heterologous differentiation, most commonly toward bone, cartilage, and rhabdomyoblastic elements [25]. More recently, cases with liposarcomatous differentiation have also been described [7]. Historically, thyroid angiosarcoma was once considered a form of ATC with endothelial differentiation; however, this concept has been refuted, and thyroid angiosarcoma is now regarded as a distinct clinicopathologic entity [29]. Given its marked morphologic heterogeneity, ATCs present a broad differential diagnosis, particularly with spindle cell neoplasms and sarcomatoid tumors [6, 25, 30, 31, 32]. Careful diagnostic evaluation is therefore required, with consideration of the differential diagnoses summarized in Table 1. Selected representative histologic patterns of anaplastic thyroid carcinoma (ATC), demonstrating a subset of the spectrum described in the main text. (A) Epithelioid type: Atypical epithelioid cells with amphophilic cytoplasm and prominent nucleoli show sheet‐like growth. (B) Spindle cell type: Fascicles of atypical spindle cells intersect, resembling spindle cell sarcoma. (C) Pleomorphic giant cell type: Pleomorphic and bizarre tumor cells exhibit a discohesive growth pattern. (D) Osteoclast‐like giant cell type: Multiple non‐neoplastic osteoclast‐like giant cells are admixed with neoplastic mononuclear cells. (E) Squamous cell type: Tumor cells exhibit sheet‐like growth with overt keratinization. (F) Rhabdoid cell type: Intracytoplasmic hyaline inclusions that displace nuclei eccentrically. TABLE 1Differential diagnosis of anaplastic thyroid carcinoma.Differential diagnosesMorphologic and clinical featuresImmunohistochemical markersMolecular featuresPoorly differentiated thyroid carcinoma Large solitary mass with occasional rapid growthDistant metastasis at presentation (20%)Solid, trabecular, or insular growth patternMonomorphic cells with minimal pleomorphism Pos: CK, TTF‐1, PAX8 TG: negative or focally positive Ki‐67 LI: 10%–30% Considerable overlap with ATCHigh‐grade differentiated thyroid carcinoma Large solitary mass with occasional rapid growthDistant metastasis at presentation (20%)Retention of well‐differentiated histologic featuresLacking anaplastic cellular morphology Pos: CK, TTF‐1, PAX8 TG: negative or focally positive Ki‐67 LI: 10%–30% Considerable overlap with ATCPTC with squamous metaplasia Focal or extensive squamous differentiationRetained PTC nuclear features without pleomorphismLow mitotic activity and no necrosis Pos: TTF‐1, PAX8 p53 wild‐type pattern Ki‐67 LI: low BRAF, RAS, RET fusionPTC and follicular neoplasm with spindle cell change Focal or extensive spindle cell changeAbsence of pleomorphismLow mitotic activity and no necrosis Pos: TTF‐1, PAX8 p53 wild‐type pattern Ki‐67 LI: low BRAF, RAS, RET fusionMedullary thyroid carcinoma Younger patients (45–55 years in sporadic cases)Occasional spindle, plasmacytoid, or pleomorphic patternAmyloid deposition Pos: calcitonin, CEA, TTF‐1 Neg: TG, PAX8 (monoclonal) RET, RAS Spindle epithelial tumor with thymus‐like elements (SETTLE) Young patients (19 years on average)Monophasic or biphasic patternLow mitotic activity Pos: SMA, p40, p63 Neg: TTF‐1, TG, PAX8 Ki‐67 LI: low Limited molecular data availableIntrathyroidal thymic carcinoma Common in Asian peopleYounger patients (52 years on average)Squamoid cell nests separated by fibrous stromaLymphoplasmacytic infiltrationLow mitotic activity and mild nuclear atypia Pos: CD5, c‐KIT, p40, p63 Neg: TTF‐1, TG, PAX8 No BRAF or RAS mutations EGFR and TERT promoter mutations in a subset of cases NUT carcinoma in thyroid Usually young patients (38 years on average)Sheet‐like growth of monomorphic round cellsDistinct nucleoli and vesicular chromatin in nucleusFrequent squamous differentiation Pos: NUT, p40, p63 Neg: PAX8, TTF‐1 (in tumors with typical NUT carcinoma morphology) NUTM1 fusion No BRAF or RAS mutations Parathyroid carcinoma Monomorphic tumor cellsVariable admixture of clear cellsSolid, trabecular growth with occasional follicular pattern Pos: neuroendocrine markers, PTH, GATA3 Neg: TTF‐1, TG, PAX8 *Loss of parafibromin CDC73 No BRAF or RAS mutations Sarcomas (e.g., synovial sarcoma, leiomyosarcoma, or angiosarcoma) Variable microscopic patterns by tumor typeAbsence of a coexisting differentiated thyroid component Neg: TTF‐1, TG, PAX8 *Confirmation of sarcoma‐specific immunophenotype * Variable CK expression No BRAF or RAS mutations Sarcoma‐specific genetic alterations Melanoma Metastatic and, less frequently, primary melanomaVariable histologic patternMelanin pigmentation (if present)Absence of a coexisting differentiated thyroid component Pos: S‐100, SOX10, HMB45, Melan‐A Neg: CK, TTF‐1, TG, PAX8 BRAF or RAS mutations in a subset of melanoma cases Lymphoma, particularly diffuse large B‐cell lymphoma (DLBCL) Diffuse infiltration of medium to large lymphoid cellsMitotic activity is often briskNecrosis is commonAbsence of a coexisting differentiated thyroid component Pos: CD45 along with other lymphoid markers Neg: CK, TTF‐1, TG, PAX8 BRAF or RAS mutations in rare cases Riedel thyroiditis Younger patients (45–50 years on average)Extensive fibrosis with lymphoplasmacytic infiltrationDistinction from paucicellular variant ATC Neg: CK, TTF‐1, TG, PAX8 *IgG4‐positive plasma cells Not applicableUpper aerodigestive tract squamous cell carcinoma with thyroid invasion Centered in mucosa of aerodigestive tractAbsence of a coexisting differentiated thyroid component Neg: TTF‐1, TG, PAX8No BRAF or RAS mutationsMetastatic carcinoma Squamous or undifferentiated morphologyAbsence of a coexisting differentiated thyroid component Pos: Site specific markers Neg: TTF‐1, TG, PAX8 VariableAbbreviations: ATC, anaplastic thyroid carcinoma; CK, cytokeratin; LI, labeling index; Neg, negative; Pos, positive; PTC, papillary thyroid carcinoma; TG, thyroglobulin. Differential diagnosis of anaplastic thyroid carcinoma. Large solitary mass with occasional rapid growth Large solitary mass with occasional rapid growth Distant metastasis at presentation (20%) Distant metastasis at presentation (20%) Solid, trabecular, or insular growth pattern Solid, trabecular, or insular growth pattern Monomorphic cells with minimal pleomorphism Monomorphic cells with minimal pleomorphism Pos: CK, TTF‐1, PAX8 TG: negative or focally positive Ki‐67 LI: 10%–30% Large solitary mass with occasional rapid growth Large solitary mass with occasional rapid growth Distant metastasis at presentation (20%) Distant metastasis at presentation (20%) Retention of well‐differentiated histologic features Retention of well‐differentiated histologic features Lacking anaplastic cellular morphology Lacking anaplastic cellular morphology Pos: CK, TTF‐1, PAX8 TG: negative or focally positive Ki‐67 LI: 10%–30% Focal or extensive squamous differentiation Focal or extensive squamous differentiation Retained PTC nuclear features without pleomorphism Retained PTC nuclear features without pleomorphism Low mitotic activity and no necrosis Low mitotic activity and no necrosis Pos: TTF‐1, PAX8 p53 wild‐type pattern Ki‐67 LI: low Focal or extensive spindle cell change Focal or extensive spindle cell change Absence of pleomorphism Absence of pleomorphism Low mitotic activity and no necrosis Low mitotic activity and no necrosis Pos: TTF‐1, PAX8 p53 wild‐type pattern Ki‐67 LI: low Younger patients (45–55 years in sporadic cases) Younger patients (45–55 years in sporadic cases) Occasional spindle, plasmacytoid, or pleomorphic pattern Occasional spindle, plasmacytoid, or pleomorphic pattern Amyloid deposition Amyloid deposition Pos: calcitonin, CEA, TTF‐1 Neg: TG, PAX8 (monoclonal) Young patients (19 years on average) Young patients (19 years on average) Monophasic or biphasic pattern Monophasic or biphasic pattern Low mitotic activity Low mitotic activity Pos: SMA, p40, p63 Neg: TTF‐1, TG, PAX8 Ki‐67 LI: low Common in Asian people Common in Asian people Younger patients (52 years on average) Younger patients (52 years on average) Squamoid cell nests separated by fibrous stroma Squamoid cell nests separated by fibrous stroma Lymphoplasmacytic infiltration Lymphoplasmacytic infiltration Low mitotic activity and mild nuclear atypia Low mitotic activity and mild nuclear atypia Pos: CD5, c‐KIT, p40, p63 Neg: TTF‐1, TG, PAX8 No BRAF or RAS mutations EGFR and TERT promoter mutations in a subset of cases Usually young patients (38 years on average) Usually young patients (38 years on average) Sheet‐like growth of monomorphic round cells Sheet‐like growth of monomorphic round cells Distinct nucleoli and vesicular chromatin in nucleus Distinct nucleoli and vesicular chromatin in nucleus Frequent squamous differentiation Frequent squamous differentiation Pos: NUT, p40, p63 Neg: PAX8, TTF‐1 (in tumors with typical NUT carcinoma morphology) NUTM1 fusion No BRAF or RAS mutations Monomorphic tumor cells Monomorphic tumor cells Variable admixture of clear cells Variable admixture of clear cells Solid, trabecular growth with occasional follicular pattern Solid, trabecular growth with occasional follicular pattern Pos: neuroendocrine markers, PTH, GATA3 Neg: TTF‐1, TG, PAX8 *Loss of parafibromin CDC73 No BRAF or RAS mutations Variable microscopic patterns by tumor type Variable microscopic patterns by tumor type Absence of a coexisting differentiated thyroid component Absence of a coexisting differentiated thyroid component Neg: TTF‐1, TG, PAX8 *Confirmation of sarcoma‐specific immunophenotype * Variable CK expression No BRAF or RAS mutations Sarcoma‐specific genetic alterations Metastatic and, less frequently, primary melanoma Metastatic and, less frequently, primary melanoma Variable histologic pattern Variable histologic pattern Melanin pigmentation (if present) Melanin pigmentation (if present) Absence of a coexisting differentiated thyroid component Absence of a coexisting differentiated thyroid component Pos: S‐100, SOX10, HMB45, Melan‐A Neg: CK, TTF‐1, TG, PAX8 BRAF or RAS mutations in a subset of melanoma cases Diffuse infiltration of medium to large lymphoid cells Diffuse infiltration of medium to large lymphoid cells Mitotic activity is often brisk Mitotic activity is often brisk Necrosis is common Necrosis is common Absence of a coexisting differentiated thyroid component Absence of a coexisting differentiated thyroid component Pos: CD45 along with other lymphoid markers Neg: CK, TTF‐1, TG, PAX8 BRAF or RAS mutations in rare cases Younger patients (45–50 years on average) Younger patients (45–50 years on average) Extensive fibrosis with lymphoplasmacytic infiltration Extensive fibrosis with lymphoplasmacytic infiltration Distinction from paucicellular variant ATC Distinction from paucicellular variant ATC Neg: CK, TTF‐1, TG, PAX8 *IgG4‐positive plasma cells Centered in mucosa of aerodigestive tract Centered in mucosa of aerodigestive tract Absence of a coexisting differentiated thyroid component Absence of a coexisting differentiated thyroid component Squamous or undifferentiated morphology Squamous or undifferentiated morphology Absence of a coexisting differentiated thyroid component Absence of a coexisting differentiated thyroid component Pos: Site specific markers Neg: TTF‐1, TG, PAX8 Abbreviations: ATC, anaplastic thyroid carcinoma; CK, cytokeratin; LI, labeling index; Neg, negative; Pos, positive; PTC, papillary thyroid carcinoma; TG, thyroglobulin. Squamous Cell Carcinoma and ATC Squamous cell carcinoma (SCC) is reported to account for approximately 20% of ATCs [5] and typically demonstrates a non‐keratinizing SCC morphology on microscopic examination [33]. Squamous components may be present only focally within a tumor, or the tumor may be composed entirely of SCC elements. Up to the fourth edition of the WHO Classification, primary SCC of the thyroid was defined as a tumor showing diffuse squamous differentiation throughout the lesion without an identifiable component of other thyroid carcinomas, including differentiated carcinomas [34]. However, in the fifth edition of the WHO Classification, the category of primary thyroid SCC was eliminated, and SCC is now classified as a subtype of ATC. This reclassification is based on several observations. SCCs arising in the thyroid frequently harbor BRAF p.V600E mutations regardless of the presence or absence of a DTC component. In addition, their clinical prognosis is largely comparable to that of conventional ATC, and they often express thyroid differentiation markers such as paired box gene 8 (PAX8) and thyroid transcription factor‐1 (TTF‐1) [5, 22]. Nevertheless, some investigators argue that primary thyroid SCC should remain a distinct entity. This view is supported by reports suggesting a different genetic profile compared with ATC, including a lower frequency of BRAF mutations and a higher prevalence of TET1 gene mutations [35]. Novel Application of Immunohistochemistry in ATC Diagnosis In the diagnosis of ATC, immunohistochemistry serves several purposes. It helps confirm the epithelial nature of the tumor, assess follicular epithelial differentiation, infer underlying molecular alterations, and distinguish ATC from other thyroid carcinomas. Common immunohistochemical markers used in routine practice include cytokeratins, thyroid differentiation markers such as thyroglobulin, TTF‐1, and PAX8, p53, Ki‐67, and mutation‐specific antibodies targeting BRAF p.V600E and RAS p.Q61R, whereas several newer markers remain investigational. Among epithelial markers, ATC usually expresses cytokeratins. However, approximately 30% of cases are negative for pan‐cytokeratin such as AE1/AE3. Even in cytokeratin‐positive tumors, staining is often focal [5]. Claudin‐4 has also increasingly been used as an epithelial marker, although its reported positivity rate in ATC remains limited to approximately 30% [36]. Thyroglobulin, TTF‐1, and PAX8 are commonly employed to evaluate follicular epithelial origin. Thyroglobulin is virtually always negative in ATC [5]. TTF‐1 is a standard marker of follicular epithelial differentiation, but its positivity rate in ATC is only about 30%. Therefore, a negative result does not exclude ATC [5]. Loss of TTF‐1 expression is thought to be associated with methylation of the TTF‐1 promoter region [37]. In contrast, PAX8 is positive in approximately 70% of ATCs. Its inclusion is therefore recommended when evaluating follicular epithelial origin in ATC [38, 39]. However, it should be noted that much of the available evidence was generated using polyclonal PAX8 antibodies. When monoclonal antibodies are used, the reported positivity rate decreases to approximately 50% [40]. TP53 gene mutations are identified in more than half of ATC cases [5, 12, 13, 41]. Correspondingly, immunohistochemistry often demonstrates either diffuse strong nuclear p53 overexpression or a complete loss of expression. However, detailed data on concordance between TP53 mutations and p53 staining patterns remain limited. In addition, standardized interpretation criteria have not been firmly established. In the literature, cutoff values for diffuse strong positivity are typically defined as staining in approximately 50%–80% of tumor cells. Under these criteria, concordance rates are generally reported to be 70%–80% [17, 24]. Mutation‐specific immunohistochemistry has also become increasingly important in ATC. Antibodies targeting BRAF p.V600E and RAS p.Q61R mutations enable rapid immunohistochemical estimation of the underlying genetic status. Both markers have shown good concordance with corresponding gene mutations in thyroid carcinomas, including ATC [42, 43, 44, 45, 46] (Figure 2). In particular, identification of BRAF p.V600E is clinically important because ATCs harboring this mutation may respond to combined BRAF and MEK inhibitor therapy [47, 48] This highlights the importance of rapid immunohistochemical/molecular testing at the time of diagnosis to guide treatment decisions [49]. Immunohistochemistry using mutation‐specific antibodies. (A, B) Anaplastic thyroid carcinoma (ATC) with squamous cell carcinoma phenotype harboring a BRAF p.V600E mutation (left). Immunohistochemistry with a mutation‐specific BRAF V600E antibody demonstrates positive staining (right). (C, D) ATC with an epithelioid pattern harboring an NRAS p.Q61R mutation (left). Immunohistochemistry with a mutation‐specific RAS Q61R antibody shows positive staining (right). In addition to these established markers, several emerging immunohistochemical markers for ATC have recently been proposed. However, most of these markers remain investigational and require further validation. Special AT‐rich Sequence‐Binding Protein 2 (SATB2) has been reported as a potential marker for ATC. However, its diagnostic utility appears limited because of substantial variability in reported positivity rates across studies and its frequent expression in a variety of other tumor types [36, 50]. In addition, unlike other thyroid carcinomas, many cases of ATC have been reported to show strong positivity for CD10 [26, 51]. More recently, transcriptomic approaches have identified several candidate markers that may be more specifically expressed in ATC. Using RNA sequencing, Haase et al. reported IGF2BP1 as a marker selectively expressed in ATC among various thyroid lesions [52]. In addition, Haq et al., employing spatial transcriptomic analysis, identified several genes—including COL7A1, LAMC2, SPHK1, and SRPX2—that are highly expressed in ATC cells and proposed these molecules as potential ATC‐specific immunohistochemical markers [53]. Although these findings are promising, their diagnostic utility in routine pathology practice has not yet been fully established. Immune‐related biomarkers have also attracted increasing attention in ATC. Immune checkpoint inhibitors targeting the programmed death‐1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) axis are widely used in the treatment of various cancers. Several clinical trials have also been conducted in ATC, in which PD‐L1 immunohistochemistry has been utilized as a predictive biomarker of therapeutic response [54]. While the positive rate of PD‐L1 is relatively low in DTC, approximately 70% of ATCs have been reported to express PD‐L1 [55]. Moreover, during progression from DTC to ATC, PD‐L1 expression patterns often shift from negative to positive [56]. Molecular Landscape of ATC Promoter mutations of TERT, which encodes the catalytic subunit of telomerase, are the most frequent genetic alterations in ATC, occurring in approximately 70% of cases. The most common mutations are c.–124C>T (C228T), followed by c.–146C>T (C250T). In addition to these promoter mutations, copy number amplification of the TERT gene has also been reported, suggesting alternative mechanisms of TERT activation [57, 58]. The second most common alteration in ATC is mutation of the TP53 gene, followed by mutations in BRAF and RAS, which serve as central oncogenic drivers of the MAPK signaling pathway. Because BRAF and RAS mutations are commonly observed in DTCs, they are considered molecular markers reflecting the differentiated precursors of ATC. Specifically, BRAF‐mutated ATCs predominantly arise from papillary thyroid carcinoma (PTC), whereas RAS‐mutated ATCs are presumed to originate from follicular thyroid carcinoma (FTC), oncocytic carcinoma, or the follicular variant of PTC [12, 16, 17, 20, 59]. While BRAF and RAS mutations occur early in tumorigenesis, TERT promoter mutations and TP53 alterations are typically late events that contribute to tumor progression (Figure 3). In particular, TERT promoter mutations have also been confirmed in a large proportion of DTC coexisting with ATC within the same tumor, underscoring their critical role in the transition from DTC to ATC [16, 17, 21, 60]. Within the MAPK pathway, NF1 alterations are identified in approximately 10% of ATCs and are largely mutually exclusive with BRAF and RAS mutations [13, 15]. In addition, although rare, ATCs harboring fusion genes involving receptor tyrosine kinases such as RET, NTRK, and ALK have also been reported [5]. PTEN and PIK3CA are key components of the PI3K/AKT signaling pathway, and alterations in these genes are frequently observed in ATC. PIK3CA mutations often co‐occur with BRAF mutations, whereas PTEN alterations tend to be associated with NF1 alterations [5, 13]. Mutations in EIF1AX, which encodes the eukaryotic translation initiation factor 1A (eIF1A) component of the 43S preinitiation complex, are detected in about 10% of ATCs, most of which harbor concurrent RAS mutations. Reflecting this molecular profile, EIF1AX‐mutated ATCs are observed in cases arising from FTC. In FTCs that progress to ATC, TERT promoter mutations are commonly found alongside RAS and EIF1AX mutations [17]. In ATC, genetic alterations involving epigenetic regulators—including histone methyltransferases, components of the SWI/SNF chromatin remodeling complex, and histone acetyltransferases—are frequently observed. These alterations are uncommon in DTCs and are thought to play an important role in tumor progression; however, their precise biological significance remains largely unclear. Additionally, ATC occasionally exhibits mutations in genes involved in DNA damage repair, including those associated with mismatch repair and homologous recombination pathways [14, 61]. Illustrative example of genetic evolution in anaplastic thyroid carcinoma (ATC) arising in a 76‐year‐old man. (A) ATC arising in the background of follicular thyroid carcinoma (FTC). (B, C) Whole‐exome sequencing reveals shared TERT promoter, HRAS, and EIF1AX mutations in both the FTC (B) and ATC (C) components, whereas TP53 and EP300 mutations are restricted to the ATC component, indicating acquisition of additional genetic alterations during tumor progression in this case. Modified from Odate et al. [17] Conclusions ATC remains one of the most aggressive malignancies; however, significant advances have been made in understanding its molecular pathogenesis and diagnostic features. Genomic studies have elucidated the stepwise progression from DTC to ATC (Figure 4). Nevertheless, the diagnosis of ATC remains challenging, particularly in limited biopsy specimens such as core needle biopsies. From a practical diagnostic standpoint, awareness of the diverse histologic spectrum of ATC and the appropriate use of immunohistochemical panels are essential for distinguishing ATC from its mimics. In addition, early integration of molecular testing, along with immunohistochemistry including mutation‐specific antibodies, should be considered in diagnostically challenging cases or when targeted therapy is being contemplated (Figure 5). Continued integration of morphologic, immunophenotypic, and genomic data will be essential to further refine diagnosis and improve clinical outcomes in this highly lethal disease. Schematic overview of progression from differentiated thyroid carcinoma (DTC) to anaplastic thyroid carcinoma (ATC). ATC primarily develops via two pathways: the BRAF p.V600E‐mutated papillary thyroid carcinoma (PTC) pathway and the RAS‐mutated pathway. The RAS‐mutated pathway includes three types of thyroid carcinomas as a precursor lesion: follicular thyroid carcinoma (FTC), oncocytic carcinoma (OC), and follicular variant of papillary thyroid carcinoma (FVPTC). The origin and progression of BRAF/RAS‐wildtype ATC remain unclear. MMR, mismatch repair; HMT, histone methyltransferase. Practical diagnostic approach to anaplastic thyroid carcinoma (ATC), integrating clinical, histologic, immunohistochemical, and molecular findings. Author Contributions Toru Odate: conceptualization, writing – original draft, writing – review and editing, visualization, funding acquisition, project administration, data curation. Tetsuo Kondo: writing – review and editing, supervision. Funding This work was supported by the Japan Society for the Promotion of Science (23K14493). Disclosure The authors have nothing to report. Ethics Statement The authors have nothing to report. Consent The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgments The authors used ChatGPT (OpenAI) for English language editing of this manuscript. Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analyzed during the current study. References Associated Data Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.